Pancreatic Cancer Research

ResearcherMie UniversityActive in the last 2 years

Kazuyuki Gyoten

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1575-4388; OpenAlex author ID A5090542384. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2021: 2 papers · 2022: 4 papers · 2023: 1 paper · 2024: none · 2025: 4 papers

Papers 11

  1. Long-term survival analysis based on tumor location in patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy following neoadjuvant chemor… Co-author DOI 10.1007/s00423-025-03609-8↗
  2. Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. Co-author DOI 10.1016/j.suronc.2025.102269↗
  3. Prognostic impacts of biological and conditional factors in patients with anatomically resectable pancreatic adenocarcinoma treated with preoperative chemoradi… Co-author DOI 10.1097/md.0000000000042441↗
  4. Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resection After Preoperative Chemoradiotherap… Co-author DOI 10.1097/mpa.0000000000002440↗
  5. Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemor… Co-author DOI 10.1016/j.hpb.2023.06.015↗
  6. Concomitant splenic artery ligation has no preventive effect on left-sided portal hypertension following pancreaticoduodenectomy with the resection of the port… Co-author DOI 10.1002/ags3.12545↗
  7. Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma: CEA Level Before Operation is a Significant Prognostic Indicator … Co-author DOI 10.1097/sla.0000000000004148↗
  8. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preopera… Co-author DOI 10.1371/journal.pone.0264573↗
  9. Involvement of superior mesenteric vein and superior mesenteric artery is adverse prognostic factors in patients with localized pancreatic ductal adenocarcinom… Co-author DOI 10.21203/rs.3.rs-2229927/v1↗
  10. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic… Co-author DOI 10.1016/j.pan.2021.08.011↗
  11. Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Con… Co-author DOI 10.1097/mpa.0000000000001902↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasuhiro Murata · 11 shared papers, 2021–2025 · strength 1.78
  2. Aoi Hayasaki · 11 shared papers, 2021–2025 · strength 1.78
  3. Shugo Mizuno · 11 shared papers, 2021–2025 · strength 1.78
  4. Naohisa Kuriyama · 11 shared papers, 2021–2025 · strength 1.78
  5. Masashi Kishiwada · 11 shared papers, 2021–2025 · strength 1.78
  6. Takahiro Ito · 8 shared papers, 2022–2025 · strength 1.42
  7. Benson Kaluba · 5 shared papers, 2022–2025 · strength 0.90
  8. Toru Shinkai · 5 shared papers, 2021–2025 · strength 0.80
  9. Hiroyuki Sakurai · 5 shared papers, 2021–2022 · strength 0.64
  10. Shuji Isaji · 5 shared papers, 2021–2023 · strength 0.64
  11. Miki Usui · 1 shared paper, 2025 · strength 0.20
  12. Masatoshi Watanabe · 1 shared paper, 2025 · strength 0.20
  13. Hiroyuki Kato · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.